Core Insights - Zai Lab is advancing its global oncology pipeline with a focus on zoci, a DLL3-targeting antibody-drug conjugate, which is in a global registrational Phase III study for small cell lung cancer (SCLC) and neuroendocrine carcinomas (NECs) [2][6][3] - The company anticipates an accelerated approval submission for zoci in 2027 and a first global approval in 2028, with promising clinical activity demonstrated in patients with brain metastases [1][6][3] - Zai Lab's commercially profitable business in China is funding its global R&D efforts, with fourth-quarter revenue increasing by 17% year-over-year to $127.6 million and a full-year revenue of $460 million [5][14] Pipeline Development - Zai Lab has initiated a global registrational Phase III study for zoci, targeting approximately 480 patients, with enrollment expected to reach 75% by the end of 2026 [2][6] - Additional pipeline developments include ZL-6201, which has received U.S. IND clearance and is entering a global Phase I study, and ZL-1222, which is progressing through IND-enabling studies [4][8] - The company is also advancing ZL-1503 for atopic dermatitis and plans to present initial data for NECs in the first half of 2026 [9][10] Financial Performance - Zai Lab reported a 19% improvement in operating loss to $229.4 million for the full year, with cash reserves of $790 million as it aims for corporate cash-flow breakeven [5][21] - R&D expenses decreased by 6% year-over-year, while SG&A expenses also saw a reduction, contributing to improved financial leverage [20][21] - The company expects a more measured growth profile in 2026, influenced by pricing dynamics and competition, while maintaining a long-term growth trajectory supported by guideline expansions [15][22] Strategic Focus - Zai Lab is focusing on building a globally innovative company, leveraging its China business for stability and funding [3] - The company is exploring first-line SCLC combination strategies and strengthening its oncology platform through targeted collaborations [13] - Zai Lab plans to initiate the commercial launch of KarXT in the second quarter of 2026, emphasizing disease awareness and clinical confidence [17]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue increased by 17% year-over-year to $127.6 million, with full-year revenues growing by 15% to $460.2 million [20][21] - Loss from operations improved by 19% for the full year to $229.4 million, and improved by 25% when adjusted for non-cash expenses [21] - The company ended the quarter with a strong cash position of $790 million [21] Business Line Data and Key Metrics Changes - The China business provided stability, with full-year revenue growth of 15% year-over-year [6] - XACDURO and NUZYRA contributed significantly to revenue growth, with XACDURO showing strong patient demand despite supply constraints [20] - VYVGART's revenue was stable, but Q4 reflected channel dynamics related to NRDL renewal and hospital purchasing patterns [17] Market Data and Key Metrics Changes - The company anticipates good growth opportunities for VYVGART and ZEJULA in 2026, despite facing a generic market for Lynparza [24] - The total addressable market for Zoci in small cell lung cancer and neuroendocrine carcinomas is estimated to exceed $9 billion [11] Company Strategy and Development Direction - The company is focused on execution and preparation for 2026, with several pipeline catalysts expected [6] - Business development remains a key lever, with targeted collaborations to explore novel combination strategies in oncology [17] - The company aims to build a lasting difference for patients while creating substantial value for shareholders [7] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of maintaining commercial profitability and preparing for multiple growth opportunities in 2026 [19] - The company is focused on strengthening its regional business and executing across its global pipeline [21] - Management expressed confidence in achieving corporate profitability, driven by top-line growth and disciplined investment [45] Other Important Information - The company has advanced Zoci from IND to global phase 3 in less than two years, reflecting the strength of its integrated U.S. and China development model [5] - The company is preparing for the commercial launch of KarXT in the second quarter of 2026, with a focus on building disease awareness and clinical confidence [19] Q&A Session Summary Question: Can you provide any color on how we should be thinking about revenues and expenses for 2026? - Management expects good growth opportunities for VYVGART and ZEJULA, with modest investments required to support launches [24][25] Question: Can you remind us of the implications of the intracranial activity in patients with brain mets for Zoci? - Zoci has shown an 80% response rate in patients with untreated brain metastases, which is a significant advantage [28] Question: Can you elaborate on the U.S., China development model? - The model allows for speedy development in China, which has led to successful registrations and efficient global trial participation [34][35] Question: What is the expectation for completion of enrollment and timing for Zoci's primary endpoint? - Enrollment is expected to finish by the end of Q1 2027, with a goal for accelerated approval in 2028 [50] Question: What is the strategy to grow VYVGART? - The focus is on increasing cycles per patient to a minimum of three, leveraging updated national guidelines [53][55]

Core Viewpoint - Zai Ding Pharma reported a 14% year-on-year increase in total revenue for Q3 2025, reaching $116.1 million, with a narrowed operating loss of $48.8 million, down 28% year-on-year, and an adjusted operating loss reduced by 42% to $28 million. The company has adjusted its full-year revenue guidance for 2025 to at least $460 million [1] Financial Performance - Total revenue for Q3 2025 was $116.1 million, a 14% increase compared to the previous year [1] - Product revenue net amounted to $115.4 million, up 13% from $101.8 million in the same period of 2024, with a 14% increase when adjusted for constant exchange rates [1] - The operating loss was $48.8 million, a reduction of 28% year-on-year, while the adjusted operating loss was $28 million, down 42% [1] Growth Drivers - The revenue growth was primarily driven by increased sales of Zocor and Dingyoule, partially offset by a slowdown in sales of Zele [1] - The company is entering a new growth phase, supported by its commercial capabilities in China and a robust pipeline of global projects [1] Future Outlook - The company is preparing for the upcoming launch of KarXT in the schizophrenia field, while continuing to strengthen the foundation for the launch of Aigamod in the myasthenia gravis area [1] - There is a steady increase in the number of new patients starting treatment and an extension in treatment duration for Aigamod, indicating growing confidence among doctors [1]